Europe Blood Collection Tubes for Liquid Biopsy Market Forecast to 2031 - Regional Analysis - by Product, Material, Application [In-Vitro Diagnostics and Research], and End User

The Europe blood collection tubes for liquid biopsy market was valued at US$ 30.94 billion in 2023 and is expected to reach US$ 1,21,742.27 million by 2031; it is estimated to register a CAGR of 18.7% from 2023 to 2031.

Advantages of Liquid Biopsy Over Other Diagnostic Testing Techniques Drive Europe Blood Collection Tubes for Liquid Biopsy Market

Invasive diagnostic procedures increase the risk of hematoma, hemorrhage, and tissue damage, seeding tumor cells in surrounding tissues. As a result, there is a growing preference for noninvasive or minimally invasive tests among patients for diagnostic purposes. Researchers can trace all genetic and epigenetic changes in solid tumors through the liquid biopsy of blood samples. Patients are at lesser risk with liquid biopsies, since it is a noninvasive technique of diagnosis. Moreover, clinicians can readily conduct these tests multiple times, as the procedures don’t subject patients to much discomfort.

Patients prefer minimally invasive procedures due to the use of advanced instruments, which allow clinicians or laboratory personnel to perform more delicate and complex work with less pain, scarring, and risk. Liquid biopsy has recently gathered considerable interest as a noninvasive alternative to tissue biopsy in cancer patients, owing to technological advancements contributing to improved feasibility and reduced processing times.

Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scan, among other imaging techniques, are expensive and time-consuming. Moreover, they expose patients to external radiation, intravenous contrast, and radioactive tracers, among others. Imaging studies also fail to provide any information about the phenotype of the tumor, which can change with the treatment given. Although tissue biopsy techniques can offer information on tumor phenotype information, it is not feasible to perform serial tissue biopsies, considering cost limitations and risks to patients.

Liquid biopsy, on the contrary, could provide a virtually continuous assessment of cancer burden and phenotype information at a relatively low cost. Liquid biopsy offers noninvasive or minimally invasive means of assessing various physiological or pathophysiological processes, thereby replacing tissue biopsy or other invasive procedures. Liquid biopsy, in this case, could circumvent the need for endoscopy, needle biopsy, or surgery by analyzing a blood sample for circulating tumor cells or circulating free nucleic acids.

Europe Blood Collection Tubes for Liquid Biopsy Market Overview

According to the “Lung Cancer in Germany” article, published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively. The average age at which individuals are diagnosed with cancer is 70 years in men and 69 years in women, and 52% of the total patients are at stage IV. The increasing prevalence of cancer thus fuels the growth of the blood collection tubes for liquid biopsy market in Germany.

Moreover, BARMER covers the OncoBEAM RAS CRC IVD Test performed in colorectal cancer patients. This innovative liquid biopsy diagnostic method delivers a comprehensive evaluation of RAS mutations using blood volume as low as a single tube. This reimbursement option marks an important milestone in the modernization of oncology care, granting patients access to critical information for the timely selection of the most appropriate therapy.

Europe Blood Collection Tubes for Liquid Biopsy Market Revenue and Forecast to 2031 (US$ Million)

Europe Blood Collection Tubes for Liquid Biopsy Market Segmentation

The Europe blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.

By product, the Europe blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the Europe blood collection tubes for liquid biopsy market share in 2023.

In terms of material, the Europe blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the Europe blood collection tubes for liquid biopsy market share in 2023.

By application, the Europe blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the Europe blood collection tubes for liquid biopsy market share in 2023.

In terms of end user, the Europe blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the Europe blood collection tubes for liquid biopsy market share in 2023.

Based on country, the Europe blood collection tubes for liquid biopsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany segment held the largest share of Europe blood collection tubes for liquid biopsy market in 2023.

Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the Europe blood collection tubes for liquid biopsy market.

Reasons to buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe blood collection tubes for liquid biopsy market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the Europe blood collection tubes for liquid biopsy market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe blood collection tubes for liquid biopsy market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.